At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Bexagliflozin +1 moredrug
Likely dose
Bexagliflozin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Bexagliflozin on the Pharmacokinetics of Digoxin in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Bexagliflozin and Digoxin for Type2 Diabetes Mellitus. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with the heart failure medication digoxin. The study will evaluate whether bexagliflozin effects the amount of digoxin in your blood and how safe the study drug is and how well the study drug is tolerated when taken with digoxin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJul 2017
Primary CompletionSep 2017
TodayJul 2026
First PostedJun 23, 2017
Enrollment StartJul 24, 2017
Primary CompletionSep 17, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.0 years ago
Interventions
Bexagliflozindrug
Bexagliflozin tablets, 20 mg
Digoxindrug
2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)